• Gunnar Tepe, John Laird, Peter Schneider, Marianne Brodmann, Prakash Krishnan, Antonio Micari, Christopher Metzger, Dierk Scheinert, Thomas Zeller, David J Cohen, David B Snead, Beaux Alexander, Mario Landini, Michael R Jaff, and IN.PACT SFA Trial Investigators.
• From the RodMed Klinikum, Rosenheim, Germany (G.T.); UC Davis, Sacramento, CA (J.L.); Kaiser Permanente - Moanalua Medical Center and Clinic, Honolulu, HI (P.S.); Landeskrankenhaus - Universitätsklinikum, Graz, Austria (M.B.); The Mount Sinai Medical Center, New York, NY (P.K.); GVM Care and Research, Lugo, Italy (A.M.); Maria Eleonora Hospital, Palermo, Italy (A.M.); Wellmont Holston Valley Medical Center, Kingsport, TN (C.M.); Park-Krankenhaus Leipzig, Germany (D.S.); Universitäts-Herzzentrum Freiburg - Bad Krozingen, Germany (T.Z.); Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City School of Medicine, Kansas City, MO (D.J.C.); Medtronic, Inc., Santa Rosa, CA (D.B.S., B.A., M.L.); and Massachusetts General Hospital, Boston, MA (M.R.J.).
• Circulation. 2015 Feb 3;131(5):495-502.

BackgroundDrug-coated balloons (DCBs) have shown promise in improving the outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated balloon with percutaneous transluminal angioplasty (PTA) for the treatment of symptomatic superficial femoral and popliteal artery disease.Methods And ResultsThe IN.PACT SFA Trial is a prospective, multicenter, single-blinded, randomized trial in which 331 patients with intermittent claudication or ischemic rest pain attributable to superficial femoral and popliteal peripheral artery disease were randomly assigned in a 2:1 ratio to treatment with DCB or PTA. The primary efficacy end point was primary patency, defined as freedom from restenosis or clinically driven target lesion revascularization at 12 months. Baseline characteristics were similar between the 2 groups. Mean lesion length and the percentage of total occlusions for the DCB and PTA arms were 8.94 ± 4.89 and 8.81 ± 5.12 cm (P=0.82) and 25.8% and 19.5% (P=0.22), respectively. DCB resulted in higher primary patency versus PTA (82.2% versus 52.4%; P<0.001). The rate of clinically driven target lesion revascularization was 2.4% in the DCB arm in comparison with 20.6% in the PTA arm (P<0.001). There was a low rate of vessel thrombosis in both arms (1.4% after DCB and 3.7% after PTA [P=0.10]). There were no device- or procedure-related deaths and no major amputations.ConclusionsIn this prospective, multicenter, randomized trial, DCB was superior to PTA and had a favorable safety profile for the treatment of patients with symptomatic femoropopliteal peripheral artery disease.Clinical Trial Registration Urlhttp://www.clinicaltrials.gov. Unique Identifiers: NCT01175850 and NCT01566461.© 2014 The Authors.

28 keywords...

hide…